Shares of Rocket Pharmaceuticals surged 10.1% to $3.42 after the company reported that the first three patients treated under a revised dosing plan for its Danon disease gene therapy showed no serious safety problems — a critical milestone for a program that was shut down by regulators just last year.
• A Scary Safety Scare Is Fading From the Rearview Mirror
A patient in the original Phase 2 trial suffered a serious adverse event involving capillary leak syndrome , which led to an FDA clinical hold. The hold was lifted in under three months , and the FDA authorized a restart at a lower, recalibrated dose in three patients treated sequentially. Now, those three patients have shown no capillary leak syndrome, no blood-clotting complications, or other significant safety concerns. For shareholders, this means the program's biggest existential risk — that it might be too dangerous to continue — has meaningfully diminished.
• Three Patients Is Encouraging, but Far From Proof
The full pivotal trial is designed to evaluate 12 patients total.
Pivotal Phase 2 data aren't expected until early 2027 , and Rocket is still talking with the FDA to agree on how to dose additional patients and finish the study. A regulatory pathway update is expected in the second half of 2026. Investors are essentially paying up today for the absence of bad news, not the presence of efficacy data — a meaningful distinction in biotech.
• The Cash Cushion Buys Time, but Not Forever
With $324.4 million in cash and a roughly $45 million quarterly burn rate, Rocket has approximately 1.75 years of runway , extended into Q2 2028 after a $180 million sale of FDA priority review vouchers. That's enough to fund the Danon trial through completion — if it stays on schedule. The market cap sits around $340 million , meaning the stock trades barely above its cash pile, a sign Wall Street still assigns limited value to the pipeline.
• Analyst Targets Suggest Big Upside — or Big Disagreement
Leerink Partners recently set a $12 price target , while one analyst pegged fair value at just $3.08. That enormous spread reflects the binary nature of the bet: if the Danon therapy works and wins approval, the stock could multiply; if it doesn't, there's little else to support the valuation beyond modest revenue from its recently approved rare-disease drug. Today's rally is a sigh of relief, not a victory lap.